Advances in the diagnosis and treatment of uterine sarcomas

Discovery Medicine

Volumn 17, Issue 96, 2014, Pages 339-345

  Dizon, Don S ^a   Birrer, Michael J ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CALDESMON; DOCETAXEL; DOXORUBICIN; ESTROGEN RECEPTOR; FASCIN; GEMCITABINE; HISTONE DEACETYLASE 8; IFOSFAMIDE; PROGESTERONE RECEPTOR; PROTEIN P16; SMOOTH MUSCLE ACTIN; TAMOXIFEN; ZINC FINGER PROTEIN; HORMONE;

ADJUVANT CHEMOTHERAPY; ARTICLE; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CHROMOSOME 17; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; METASTASIS; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; UTERUS SARCOMA; CLASSIFICATION; GENETICS; NEOPLASM RECURRENCE, LOCAL; SARCOMA; UTERINE NEOPLASMS;

CHEMOTHERAPY, ADJUVANT; FEMALE; HORMONES; HUMANS; NEOPLASM RECURRENCE, LOCAL; SARCOMA; UTERINE NEOPLASMS;

EID: 84921470711     PISSN: 15396509     EISSN: 19447930     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Altman AD, Nelson GS, Chu P, Nation J, Ghatage P. Uterine sarcoma and aromatase inhibitors: Tom Baker Cancer Centre experience and review of the literature. Int J Gynecol Cancer 22(6):1006-1012, 2012.
2. Atkins KA, Arronte N, Darus CJ, Rice LW. The Use of p16 in enhancing the histologic classification of uterine smooth muscle tumors. Am J Surg Pathol 32(1):98-102, 2008.
3. Bodner K, Laubichler P, Kimberger O, Czerwenka K, Zeillinger R, Bodner-Adler B. Oestrogen and progesterone receptor expression in patients with adenocarcinoma of the uterine cervix and correlation with various clinicopathological parameters. Antica Res 30(4):1341-1345, 2010.
4. Chan JK, Kawar NM, Shin JY, Osann K, Chen LM, Powell CB, Kapp DS. Endometrial stromal sarcoma: a population-based analysis. Brit J Cancer 99(8):1210-1215, 2008.
5. Cheng X, Yang G, Schmeler KM, Coleman RL, Tu X, Liu J, Kavanagh JJ. Recurrence patterns and prognosis of endometrial stromal sarcoma and the potential of tyrosine kinase-inhibiting therapy. Gynecol Oncol 121(2):323-327, 2011.
6. Chiang S, Ali R, Melnyk N, McAlpine JN, Huntsman DG, Gilks CB, Lee CH, Oliva E. Frequency of known gene rearrangements in endometrial stromal tumors. Am J Surg Pathol 35(9):1364-1372, 2011.
7. Chiang S, Oliva E. Recent developments in uterine mesenchymal neoplasms. Histopathology 62(1):124-137, 2013.
8. D'Angelo E, Spagnoli LG, Prat J. Comparative clinicopathologic and immunohistochemical analysis of uterine sarcomas diagnosed using the World Health Organization classification system. Hum Pathol 40(11):1571-1585, 2009.
9. Edmonson JH, Blessing JA, Cosin JA, Miller DS, Cohn DE, Rotmensch J. Phase II study of mitomycin, doxorubicin, and cisplatin in the treatment of advanced uterine leiomyosarcoma: a Gynecologic Oncology Group study. Gynecol Oncol 85(3):507-510, 2002.
10. Gallup DG, Blessing JA, Andersen W, Morgan MA. Evaluation of paclitaxel in previously treated leiomyosarcoma of the uterus: a gynecologic oncology group study. Gynecol Oncol 89(1):48-51, 2003.
11. Giuntoli RL, Garrett-Mayer E, Bristow RE, Gostout BS. Secondary cytoreduction in the management of recurrent uterine leiomyosarcoma. Gynecol Oncol 106(1):82-88, 2007.
12. Giuntoli RL, Lessard-Anderson CR, Gerardi MA, Kushnir CL, Cliby WA, Metzinger DS, Gostout BS. Comparison of current staging systems and a novel staging system for uterine leiomyosarcoma. Int J Gynecol Cancer 23(5):869-876, 2013.
13. Hensley ML, Blessing JA, Mannel R, Rose PG. Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial. Gynecol Oncol 109(3):329-334, 2008a.
14. Hensley ML, Blessing JA, Degeest K, Abulafia O, Rose PG, Homesley HD. Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study. Gynecol Oncol 109(3):323-328, 2008b.
15. Hensley ML, Ishill N, Soslow R, Larkin J, Abu-Rustum N, Sabbatini P, Konner J, Tew W, Spriggs D, Aghajanian CA. Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: Results of a prospective study. Gynecol Oncol 112(3):563-567, 2009.
16. Hensley ML, Miller A, O'Malley DM, Mannel RS, Behbakht K, Bakkum-Gamez JN, Michael H. A randomized phase III trial of gemcitabine + docetaxel + bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma (uLMS): a Gynecologic Oncology Group study. Presented at the 2014 Annual Meeting for Women's Cancers, Tampa, FL. Abstr #2. 2014. Available at: https://www.sgo.org/wp-content/uploads/2014/03/ABSUPP_3.14.14.pdf. (Accessed Apr. 2, 2014.)
17. Hensley ML, Sill MW, Scribner DR, Brown J, Debernardo RL, Hartenbach EM, McCourt CM, Bosscher JR, Gehrig PA. Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study. Gynecol Oncol 115(3):460-465, 2009.
18. Hensley ML, Wathen JK, Maki RG, Araujo DM, Sutton G, Priebat DA, George S, Soslow RA, Baker LA. Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005). Cancer 119(8):1555-1561, 2013.
19. Iasonos A, Keung EZ, Zivanovic O, Mancari R, Peiretti M, Nucci M, George S, Colombo N, Carinelli S, Hensley ML, Raut CP. External validation of a prognostic nomogram for overall survival in women with uterine leiomyosarcoma. Cancer 119(10):1816-1822, 2013.
20. Karpathiou G, Sivridis E, Giatromanolaki A. Myxoid leiomyosarcoma of the uterus: a diagnostic challenge. Eur J Gyn Oncol 31(4):446-448, 2010.
21. Kefeli M, Yildiz L, Kaya FC, Aydin O, Kandemir B. Fascin expression in uterine smooth muscle tumors. Int J Gynecol Pathol 28(4):328-333, 2009.
22. Koontz JI, Soreng AL, Nucci M, Kuo FC, Pauwels P, van Den Berghe H, Dal Cin P, Fletcher JA, Sklar J. Frequent fusion of the JAZF1 and JJAZ1 genes in endometrial stromal tumors. Proc Natl Acad Sci USA 98(11):6348-6353, 2001.
23. Kurihara S, Oda Y, Ohishi Y, Iwasa A, Takahira T, Kaneki E, Kobayashi H, Wake N, Tsuneyoshi M. Endometrial stromal sarcomas and related high-grade sarcomas: immunohistochemical and molecular genetic study of 31 cases. Am J Surg Pathol 32(8):1228-1238, 2008.
24. Lee CH, Mariño-Enriquez A, Ou W, Zhu M, Ali RH, Chiang S, Amant F, Gilks CB, van de Rijn M, Oliva E, Debiec-Rychter M, Dal Cin P, Fletcher JA, Nucci MR. The clinicopathologic features of YWHAE-FAM22 endometrial stromal sarcomas: a histologically high-grade and clinically aggressive tumor. Am J Surg Pathol 36(5):641-653, 2012a.
25. Lee CH, Ou WB, Mariño-Enriquez A, Zhu M, Mayeda M, Wang Y, Guo X, Brunner AL, Amant F, French CA, West RB, McAlpine JN, Gilks CB, Yaffe MB, Prentice LM, McPHerson A, Jones SJ, Marra MA, Shah SP, van de Rijn M, et al. 14-3-3 fusion oncogenes in high-grade endometrial stromal sarcoma. Proc Natl Acad Sci USA 109(3):929-934, 2012b.
26. Lee CH, Turbin DA, Sung YC, Espinosa I, Montgomery K, van de Rijn M, Gilks CB. A panel of antibodies to determine site of origin and malignancy in smooth muscle tumors. Mod Pathol 22(12):1519-1531, 2009.
27. Leitao, MM, Brennan MF, Hensley M, Sonoda Y, Hummer A, Bhaskaran D, Venkatraman E, Alektiar K, Barakat RR. Surgical resection of pulmonary and extrapulmonary recurrences of uterine leiomyosarcoma. Gynecol Oncol 87(3):287-294, 2002.
28. Leitao MM, Hensley ML, Barakat RR, Aghajanian C, Gardner GJ, Jewell EL, O'Cearbhaill R, Soslow RA. Immunohistochemical expression of estrogen and progesterone receptors and outcomes in patients with newly diagnosed uterine leiomyosarcoma. Gynecol Oncol 124(3):558-562, 2012.
29. Leitao MM, Soslow RA, Nonaka D, Olshen AB, Aghajanian C, Sabbatini P, Dupont J, Hensley M, Sonoda Y, Barakat RR, Anderson S. Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma. Cancer 101(6):1455-1462, 2004.
30. Lim D, Alvarez T, Nucci MR, Gilks B, Longacre, T, Soslow RA, Oliva E. Interobserver variability in the interpretation of tumor cell necrosis in uterine leiomyosarcoma. Am J Surg Pathol 37(5):650-658, 2013.
31. Long HJ, Blessing JA, Sorosky J. Phase II trial of dacarbazine, mitomycin, doxorubicin, and cisplatin with sargramostim in uterine leiomyosarcoma: a Gynecologic Oncology Group study. Gynecol Oncol 99(2):339-342, 2005.
32. Look KY, Sandler A, Blessing JA, Lucci JA, Rose PG. Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) Study. Gynecol Oncol 92(2):644-647, 2004.
33. Manoharan M, Azmi MAN, Soosay G, Mould T, Weekes AR. Mullerian adenosarcoma of uterine cervix: report of three cases and review of literature. Gynecol Oncol 105(1):256-260, 2007.
34. McMeekin DS, Sill MW, Darcy KM, Stearns-Kurosawa DJ, Webster K, Waggoner S, Benbrook D. A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a gynecologic oncology group study. Gynecol Oncol 106(3):596-603, 2007.
35. Miller DS, Blessing JA, Kilgore LC, Mannel R, Van Le L. Phase II trial of topotecan in patients with advanced, persistent, or recurrent uterine leiomyosarcomas: a Gynecologic Oncology Group Study. Am J Clin Oncol 23(4):355-357, 2000.
36. Moinfar F, Azodi M, Tavassoli FA. Uterine sarcomas. Pathology 39(1):55-71, 2012.
37. Monk BJ, Blessing JA, Street DG, Muller CY, Burke JJ, Hensley ML. A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: a gynecologic oncology group study. Gynecol Oncol 124(1):48-52, 2012.
38. O'Cearbhaill R, Zhou Q, Iasonos A, Soslow RA, Leitao MM, Aghajanian C, Hensley ML. Treatment of advanced uterine leiomyosarcoma with aromatase inhibitors. Gynecol Oncol 116(3):424-429, 2010.
39. Oduyebo T, Rauh-Hain AJ, Meserve EE, Seidman MA, HinchcliffE, George S, Quade B, Nucci MR, Del Carmen MG, Muto MG. The value of re-exploration in patients with inadvertently morcellated uterine sarcoma. Gynecol Oncol 132(2):360-365, 2014.
40. Ognjanovic S, Olivier M, Bergemann TL, Hainaut P. Sarcomas in TP53 germline mutation carriers: a review of the IARC TP53 database. Cancer 118(5):1387-1396, 2012.
41. Prat J. FIGO staging for uterine sarcomas. Int J Gynaecol Obstet 104(3):177-178, 2009.
42. Reich O, Regauer S. Hormonal therapy of endometrial stromal sarcoma. Curr Opin Oncol 19(4):347-352, 2007.
43. Rose PG, Blessing JA, Soper JT, Barter JF. Prolonged oral etoposide in recurrent or advanced leiomyosarcoma of the uterus: a gynecologic oncology group study. Gynecol Oncol 70(2):267-271, 1998.
44. Rush DS, Tan J, Baergen RN, Soslow RA. h-Caldesmon, a novel smooth muscle-specific antibody, distinguishes between cellular leiomyoma and endometrial stromal sarcoma. Am J Surg Pathol 25(2):253-258, 2001.
45. Seidman MA, Oduyebo T, Muto MG, Crum CP, Nucci MR, Quade BJ. Peritoneal dissemination complicating morcellation of uterine mesenchymal neoplasms. PLoS One 7(11):e50058, 2012.
46. Shah JP, Bryant CS, Kumar S, Ali-Fehmi R, Malone JM, Morris RT. Lymphadenectomy and ovarian preservation in low-grade endometrial stromal sarcoma. Obstet Gynecol 112(5):1102-1108, 2008.
47. Shi Y, Liu Z, Peng Z, Liu H, Yang K, Yao X. The diagnosis and treatment of Mullerian adenosarcoma of the uterus. Aust NZ J Obstet Gynaecol 48(6):596-600, 2008.
48. Smith HO, Blessing JA, Vaccarello L. Trimetrexate in the treatment of recurrent or advanced leiomyosarcoma of the uterus: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 84(1):140-144, 2002.
49. Soslow RA, Ali A, Oliva E. Mullerian adenosarcomas: an immunophenotypic analysis of 35 cases. Am J Surg Pathol 32(7):1013-1021, 2008.
50. Sutton G, Blessing JA, Ball H. Phase II trial of paclitaxel in leiomyosarcoma of the uterus: a gynecologic oncology group study. Gynecol Onol 74(3):346-349, 1999.
51. Sutton G, Blessing J, Hanjani, P, Kramer P & Gynecologic Oncology Group. Phase II evaluation of liposomal doxorubicin (Doxil) in recurrent or advanced leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol 96(3):749-752, 2005.
52. Taçkin S, Bozaci EA, Sönmezer M, Ekinci C, Ortaç F. Late recurrence of uterine Mullerian adenosarcoma as heterologous sarcoma: Three recurrences in 8 months increasing in number and grade of sarcomatous components. Gynecol Oncol 101(1):179-182, 2006.
53. Tanner EJ, Garg K, Leitao MM, Soslow RA, Hensley ML. High grade undifferentiated uterine sarcoma: surgery, treatment, and survival outcomes. Gynecol Oncol 127(1):27-31, 2012.
54. Tropé CG, Abeler VM, Kristensen GB. Diagnosis and treatment of sarcoma of the uterus. A review. Acta Oncol 51(6):694-705, 2012.
55. Uterine Sarcoma Treatment (PDQ®) - National Cancer Institute. Available at: http://www.cancer.gov/cancertopics/pdq/treatment/uterinesarcoma/HealthProfessional/page2#Reference2.1. Retrieved on Mar. 15, 2014.
56. Zivanovic O, Jacks LM, Iasonos A, Leitao MM, Soslow RA, Veras E, Hensley, ML. A nomogram to predict postresection 5-year overall survival for patients with uterine leiomyosarcoma. Cancer 118(3):660-669, 2012.